Lotte Biologics Signs Additional CDMO Agreement with UK Ottimo Pharma
Second Consecutive Antibody Drug Manufacturing Agreement Signed Since Last June
Lotte Biologics announced on May 18 that it has signed a contract manufacturing agreement for antibody drugs with UK-based biotechnology company Ottimo Pharma.
Lotte Biologics also signed a contract manufacturing agreement for antibody drugs with Ottimo Pharma in June last year. Through this additional contract, Lotte Biologics will be responsible for producing the active pharmaceutical ingredient (API) for Ottimo Pharma's antibody drug candidate, Jankistomig, at the Syracuse Bio Campus in New York. This contract covers not only API production, but also process development.
James Park, CEO of Lotte Biologics, stated, "Based on our integrated CDMO capabilities that cover everything from process development to commercial manufacturing, we will actively support Ottimo Pharma in successfully developing new drugs."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Spencer Fisk, Chief Technology and Quality Officer (CTQO) at Ottimo Pharma, commented, "Lotte Biologics' quick and reliable execution has played a vital role in enabling our clinical trials to proceed at an industry-leading pace. We are very pleased to further expand our collaboration as we continue development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.